Rogerio Vivaldi, Sigilon CEO (via website)

Sig­ilon fo­cus­es on type 1 di­a­betes, re­duces spend on MPS-1 af­ter let­ting CMO go (cor­rect­ed)

Sig­ilon Ther­a­peu­tics said it de­creased ex­ter­nal spend on a rare lyso­so­mal stor­age dis­or­der as the Bob Langer-found­ed biotech fo­cus­es its cell …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.